FDA Approves Pfizer and Merck's Ertugliflozin for Type 2 Diabetes
The US Food and Drug Administration (FDA) has approved ertugliflozin (Steglatro) for the treatment of glycemic control in patients with type 2 diabetes (T2D).
Ertugliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor from Merck & Co. and Pfizer, was approved as both a single therapy and fixed-dose combination therapy with dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia) or common first-line therapy metformin. The combination therapies will carry the brand names Steglujan and Segluromet, respectively.
Merck and Pfizer previously announced successfully-met endpoints for the combination therapies in 2 phase 3 trials (VERTIS MET, VERTIS SITA) in June.
Read more: http://bit.ly/ErtuglifozinApproval
Ertugliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor from Merck & Co. and Pfizer, was approved as both a single therapy and fixed-dose combination therapy with dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia) or common first-line therapy metformin. The combination therapies will carry the brand names Steglujan and Segluromet, respectively.
Merck and Pfizer previously announced successfully-met endpoints for the combination therapies in 2 phase 3 trials (VERTIS MET, VERTIS SITA) in June.
Read more: http://bit.ly/ErtuglifozinApproval
